LANSING, MI, Aug 05, 2010 (MARKETWIRE via COMTEX) — KraigBiocraft Laboratories, Inc. (OTCBB: KBLB ), a biotechnology company focused on the development of commercially significant high performance polymers including spider silk, today confirmed that earlier this year the Company entered into a new collaborative research and development agreement with the University of Notre Dame relating to the development of new polymers.

“The rate of progress and scientific development achieved over the last twelve months has exceeded our expectations. I believe that we are now ahead of our scheduled timeline for R&D and product development,” said Kim Thompson, Kraig CEO. “The new collaborative research agreement was designed to help us maintain that momentum. We are also hopeful that our recently completed S1 registration will enable the Company to further accelerate our development of new materials.”

For more information on KraigBiocraft Laboratories please visit the Company’s web site: www.KraigLabs.com

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT:

Kraig Biocraft Laboratories, Inc.

Kim K. Thompson CEO

LANSING, Mich., Jun 22, 2010 (BUSINESS WIRE) — Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB ), a biotechnology company focused on the development of commercially significant high performance polymers and technical fiber including spider silk, is very pleased to announce that its S1 registration statement has been declared effective. The Company filed the S1 registration statement in October of 2009 and has been working diligently over the last nine months to obtain this clearance.

“After working on this for nearly nine months, we are very happy to announce that the SEC has informed the Company that its S1 registration is now effective,” said CEO Kim K. Thompson. “The S1 registration lays the foundation for our financing program over the next twenty four months. When we originally filed the S1 our legal advisors told us that we could expect a delay of at least forty five days. Those forty five days ultimately turned into almost nine months. While we have been pursuing this clearance our legal advisors informed us that the Company should limit its public communication to avoid the perception of any promotion. We want to thank all of our shareholders for their patience during this arduous process and we look forward to what we now believe will be a very successful year for Kraig Biocraft Laboratories.”

Kraig is working to develop and commercialize high performance polymers using spider silk gene sequences. The company plans to tap into the $92 billion market for high performance and technical fibers. In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of scientific research and development within the university.

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: www.KraigLabs.com

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. is applying its proprietary genetic engineering technology to find solutions in the areas of material science. Kraig has obtained the exclusive right, in their field of research, for the spider silk gene sequences which are at the core of their technology. These genetic sequences were first studied and subsequently patented by Dr. Lewis of the University of Wyoming. In early 2006, the company obtained certain exclusive rights from the University to utilize the sequences in our field of use. Spider Silk is among the strongest fibers produced in nature with potentially broad applications for consumers and industry in the multi-billion dollar marketplace for high performance polymers.

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

SOURCE: Kraig Biocraft Laboratories, Inc.

CONTACT: Kraig Biocraft Laboratories, Inc. Kim K. Thompson, CEO

LANSING, Mich., May 29, 2009 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) is pleased to announce that it has successfully issued its stock dividend. “The issuance of the dividend has been in the planning for some time and has been an important part of the Company’s plan for returning value to our shareholders. Just as important, we believe that the issuance has laid the groundwork for the Company’s long term future,” said CEO Kim K Thompson. “The input we have received from our shareholders throughout this process has been and continues to be overwhelmingly positive. We are also very excited about the progress in the laboratory and are very hopeful that the scientific team can maintain their tremendous forward momentum through the summer and fall and into 2010.”

Kraig is working to develop and commercialize high performance polymers using spider silk gene sequences. The company plans to tap into the $92 billion market for high performance and technical fibers. In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of scientific research and development within the university.

For more information on Kraig Biocraft Laboratories, and to hear an audio interview with Kraig’s CEO, please visit the Company’s web site: www.KraigLabs.com

The Kraig Biocraft Laboratories, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4817

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT:

Kraig Biocraft Laboratories, Inc.
Kim K. Thompson, CEO

(517) 336-0807

LANSING, Mich., May 12, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) announce that the scientific team is preparing to significantly ramp up the number of genetic insertions performed in the month of May. The team anticipates that the rate of DNA construct insertions in May will be double that which has been performed to date.

“We are now entering the next phase in which the team is reallocating recourses to genetic insertion,” said CEO Kim Thompson.

“This is directly related to our recent development of new DNA constructs that are specifically targeted for the production of new fusion silk proteins. We intend to dramatically ramp up the number of insertions performed in order to gain the maximum benefit from the new insertion packets.”

Every targeted DNA packet insertion has the potential to create a new recombinant fiber with commercial applications.

Kraig is working to develop and commercialize high performance polymers using spider silk gene sequences. The company plans to tap into the $92 billion market for high performance and technical fibers. In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of scientific research and development within the university.

For more information on Kraig Biocraft Laboratories, and to hear an audio interview with Kraig’s CEO, please visit the Company’s web site: www.KraigLabs.com

This press release includes certain statements that may be deemed to be “forward-looking

statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com

LANSING, Mich., May 4, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) is pleased to announce that Dr. Malcolm Fraser, working in cooperation with Dr. Wang, Dr. Sohn and other members of the scientific team have recently succeeded in building eight unique DNA constructs which the team is preparing for genetic insertion over the next several weeks. These genetic insertion packets include several that are specifically targeted for the production of new fusion silk proteins.

“These constructs include a number of new DNA combinations that are truly exciting,” said CEO Kim K. Thompson. “The increases in laboratory productivity over the last eight months are now enabling us to do more and to do it faster. This number of unique genetic constructs is a new breakthrough for the Company. Each of these constructs has the potential to result in the development of a new polymer or high performance fiber.” The genetic constructs are customized packets of DNA which provide genetic instructions for the creation of new polymers and spider silk based proteins.

Over the last year, the University of Notre Dame added of Dr. Wang, Dr. Sohn and other scientists to the research team. “Since that time we have seen a dramatic increase in both the quality and quantity of the work performed,” said Thompson. “We are ready to ramp up our effort to insert as many constructs as possible,” added Dr. Fraser.

Kraig is working to develop and commercialize high performance polymers using spider silk gene sequences. The company plans to tap into the $92 billion market for high performance and technical fibers. In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of scientific research and development within the university.

For more information on Kraig Biocraft Laboratories, and to hear an audio interview with Kraig’s CEO, please visit the Company’s web site: www.KraigLabs.com

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com

LANSING, Mich., April 27, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) confirms that the record date for the stock dividend is today, April 27, 2009. The press release of April 23^rd contained a typographical error and mistakenly referred to April 27^th as the Ex Date. Stock holders are instructed to disregard the April 27 press release.

The ex date is currently set as May 28, 2009. Please use the following link to see

NASDAQ Group’s posting:

http://www.otcbb.com/asp/dividend.asp?sym_id=KBLB&dDate=4/27/2009&sDateType=Record_date

We can not provide trading advice. Please consult with your broker regarding the stock distribution. Stock holders who sell their stock today or before the ex date may be selling the right to the distribution. Please consult with your broker.

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com

LANSING, Mich., April 15, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) has declared a stock dividend. All shareholders of record as of the close of business on the record date will be issued nine additional shares for each share of common stock held. The record date is April 27, 2009.

“This stock dividend is intended to lay the groundwork for the growth of the Company,” said CEO Kim K. Thompson. “It is part of our ongoing efforts to promote capital investment, broaden ownership, improve trading liquidity, and enhance shareholder value. This action is enabled by the Company’s continued success in the laboratory and is consistent with the Board’s commitment to take actions designed to increase capital investment and create a wider distribution of the Company’s stock.”

The declaration of the stock dividend follows the announcement over the last several months of significant increases in laboratory productivity. The Company believes these dramatic increases in productivity are the direct result of the Company’s successful efforts to recruit highly talented scientists and researchers in 2008. “Ultimate credit for the increased pace of work in the laboratory belongs to Dr. Fraser and the University of Notre Dame research team,” said Kim Thompson.

Kraig is a biotechnology company developing advanced materials and high performance polymers. The Company believes that these materials have the potential to make a significant impact on the $92 billion market for high performance and technical fibers. The Company works in cooperation with leading universities and university researchers, and virtually all of the scientific research is conducted within university laboratories. For more information on Kraig Biocraft Laboratories, and to hear an audio interview with Kraig’s CEO, please visit the Company’s web site: www.KraigLabs.com

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com

LANSING, Mich., March 30, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) is very pleased to report that scientists working in the Company’s sponsored research program at the University of Notre Dame have succeeded in significantly increasing the number and proportion of DNA insertions which yield transient expression of the Company’s targeted marker protein. “These results, which are occurring in the latest generation of genetic insertions performed in the laboratory, are very exciting, and we believe that it is further evidence that research team is on the right track” said CEO Kim K. Thompson.

The increase which the team is reporting is in both absolute numbers and in the percentage of insertions which ultimately result in the expression. This progress report from the laboratory follows the Company’s announcement of the achievement of a number of milestones over the last six months. “This is the first time we have seen the number of DNA insertions yielding transient expression reach the triple digits. We do seem to be in a state of acceleration in terms of the pace of laboratory achievement,” added Mr. Thompson.

For more information on Kraig Biocraft Laboratories, please visit the Company’s web site: www.KraigLabs.com

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops”, “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

CONTACT:

Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com

EAST LANSING, Mich., March 24, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) today announced that its Board of Directors has approved a stock dividend. The Board declared that shareholders of record as of the close of business on the record date will be issued nine additional shares for each share of Common Stock held.

“This stock dividend is intended to lay the groundwork for the growth of the Company,” said CEO Kim K. Thompson. “It is part of our ongoing efforts to improve trading liquidity, broaden ownership, promote capital investment and enhance shareholder value. This action is enabled by the Company’s continued success in the laboratory and is consistent with the Board’s commitment to take actions designed to create a wider distribution of the Company’s stock.”

The Board has directed the Company’s officers to confer with market oversight authorities and its transfer agents as soon as is practical to determine a record date.

Kraig is a biotechnology company working to develop and commercialize high performance polymers using spider silk gene sequences. The company hopes to tap into the $92 billion market for high performance and technical fibers. The Company works in cooperation with leading universities and university researchers. In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of genetic research within the University.

For more information on Kraig Biocraft Laboratories, and to hear an audio interview with Kraig’s CEO, please visit the Company’s web site: www.KraigLabs.com

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com

EAST LANSING, Mich., March 23, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) is pleased to announce that Dr. Fraser reported this week that his team has “made significant progress on developing enzymes and strategies for conducting site specific genetic recombination in silkworm.”

“In the Company’s view, the development of this particular gene splicing technology is the key to unlocking the tremendous commercial potential of spider silks and other recombinant polymers,” said Kraig’s CEO, Kim K. Thompson. “Dr. Fraser’s report of this news from the laboratory is the culmination of years of scientific effort. It is a huge milestone on the path to commercialization,” continued Thompson.

“We believe that we are the only people who have this capability at this time.” Dr. Fraser emphasized.

Dr. Fraser’s team of research scientists, working within University of Notre Dame laboratories, has reported a number of significant advancements over the last four or five months. This most recent announcement follows closely on the heals of the Company’s announcement that it had achieved approximately five thousand genetic insertions, and that it had achieved the activation of fluorescent marker gene sequences which the researchers incorporated into spider silk DNA packets.

Site specific genetic recombination allows for the genetic targeting of a specific location on a specific chromosome. It is potentially critical to the Company’s work because of the strong influence of what geneticists’ refer to as “location effects.” Location effects are effects that result not from the coding of a specific gene, but from the location of that gene on a specific chromosome.

For more information on Kraig Biocraft Laboratories, please visit the Company’s web site: www.KraigLabs.com

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believe,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “seen,” “develops”, “researching,” “research,” “potential,” “path,” “progress,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com